Dermatol. praxi. 2025;19(3):98-101 | DOI: 10.36290/der.2025.018

Current treatment options for chronic spontaneous urticaria

MUDr. Iva Karlová
Klinika chorob kožních a pohlavních, LF UP a FN Olomouc

Urticaria is disease characterized by spontaneously recurring wheals, angioedema, or both, If the symptoms last longer than 6 weeks, it is chronic urticaria, which is further divided into chronic spontaneous and inducible. Chronic spontaneous urticaria affects patients of any age but is most common in females aged 30 to 50 years. Second-generation H1 antihistamines are first-line treatment if the effect is insufficient, the dose may be increased up to four fold. The 2022 international urticaria guideline recommends the monoclonal anti-IgE antibody omalizumab as second-line treatment for antihistamine-refractory chronic spontaneous urticaria. The third line of therapy is represented by Cyclosporin A.

Keywords: chronic spontaneous urticaria, non-sedating H1 antihistamines, omalizumab.

Accepted: September 23, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karlová I. Current treatment options for chronic spontaneous urticaria. Dermatol. praxi. 2025;19(3):98-101. doi: 10.36290/der.2025.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK

    References

    1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090. Epub 2021 Oct 20. PMID: 34536239. Go to original source... Go to PubMed...
    2. Kolkhir P, Bonnekoh H, Metz M, et al. Chronic Spontaneous Urticaria: A Review. JAMA. 2024 Nov 5;332(17):1464-1477. Go to original source... Go to PubMed...
    3. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Jun;149(6):1819-1831. Go to original source... Go to PubMed...
    4. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. Nat Rev Dis Primers. 2022;8(1):61. Go to original source... Go to PubMed...
    5. Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study.J Allergy Clin Immunol. 2012;129 (5):1307-1313. Go to original source... Go to PubMed...
    6. Kumar YH, Bhaskar S, Shankar K. Comparative Study of Positive Versus Negative Autologous Serum Skin Test in Chronic Spontaneous Urticaria and its Treatment Outcome. N Am J Med Sci. 2016 Jan;8(1):25-30. doi: 10.4103/1947-2714.175195. PMID: 27011944; PMCID: PMC4784180. Go to original source... Go to PubMed...
    7. Holgate ST, Canonica GW, Simons FE, et al. Consensus group of new generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003 Sep;33(9):1305-24. doi: 10.1046/j.1365-2222.2003.01769.x. PMID: 12956754. Go to original source... Go to PubMed...
    8. Ferrer M, Sastre J, Jáuregui I, et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol. 2011;21:34-39.
    9. Chang TW, Chen C, Lin ChJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. A Allergy Clin. Immunol. 2015;136(2): 337-342. Go to original source... Go to PubMed...
    10. Available from: http://www.sukl.cz.
    11. Karlová I. Využití omalizumabu v dermatologii. Dermatol. praxi. 2016;10(2):66-69. doi: 10.36290/der.2016.016. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.